BioTuesdays

Category - Markets

AC Immune
Markets

Leerink starts AC Immune at OP; PT $18

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

November 16, 2018
Adamas Pharmaceuticals Logo
Markets

Leerink starts Adamas Pharma at OP; PT $20

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

November 16, 2018
Mersana Therapeutics Logo
Markets

Leerink ups Mersana Therapeutics to OP; holds PT at $14

Leerink Partners upgraded Mersana Therapeutics (NASDAQ:MRSN) to “outperform” from “market perform” but maintained its price target of $14, citing the stock’s valuation. It closed at $6.04 on Nov. 13. “We are upgrading...

November 14, 2018
Biohaven Pharmaceuticals
Markets

Leerink starts Biohaven Pharma at OP; PT $50

Leerink Partners launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and $50 price target. The stock closed at $36.90 on Nov. 13. Biohaven is focused on a range of neurological...

November 14, 2018
Moleculin Logo
Markets

Maxim starts Moleculin Biotech at “buy”; PT $3

Maxim Group launched coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.35 on Nov. 13. Moleculin has three differentiated oncology programs: a STAT3 inhibitor for...

November 14, 2018
Matinas Biopharma
Markets

Maxim ups Matinas BioPharma PT to $5 from $2

Maxim Group raised its price target for Matinas BioPharma (NYSE American:MTNB) to $5 from $2 after the American Heart Association meeting over the weekend. The stock closed at $1.11 on Nov. 9. “We are factoring in...

November 12, 2018
AVEO Pharmaceuticals Logo
Markets

HCW ups AVEO Pharma PT to $9 from $6.50

H.C. Wainwright raised its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $9 from $6.50 after the company reported positive top line results from its Phase 3 TIVO-3 study, evaluating tivozanib for the treatment...

November 6, 2018